CALA - aim high or don't aim at all

NASDAQ:CALA   Calithera Biosciences, Inc
I expect the KEAPSAKE PH2 data to be good, which should take the stock to 12+ sp in coming months. Data is expected this Q. They have decent amount of cash to fund their trials into late 2H, 2022.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.